{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    8,
    9,
    20,
    41,
    44,
    56,
    57
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Study Schema",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2",
        "sectionTitle": "SCHEMA",
        "description": "Reference to the graphical study design"
      },
      {
        "id": "ref_2",
        "name": "Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "SCHEDULE OF ACTIVITIES (SOA)",
        "description": "Reference to the study visit and procedure tables"
      },
      {
        "id": "ref_3",
        "name": "Inhibitor Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.1.1",
        "sectionTitle": "Inhibitor development",
        "description": "Reference for the definition of inhibitor development in relation to stopping rules"
      },
      {
        "id": "ref_4",
        "name": "Regulatory Oversight",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1",
        "sectionTitle": "APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS",
        "description": "Reference for informed consent process"
      },
      {
        "id": "ref_5",
        "name": "Country Specific Requirements - Italy",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.11.2",
        "sectionTitle": "Italy",
        "description": "Reference for Italy-specific renal function exclusion criteria"
      },
      {
        "id": "ref_6",
        "name": "Country Specific Requirements - France",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.11.1",
        "sectionTitle": "France",
        "description": "Reference for France-specific end of study requirements"
      },
      {
        "id": "ref_7",
        "name": "PRO Assessments",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.2",
        "sectionTitle": "Patient reported outcomes",
        "description": "Reference for details on PROMIS and PGIS assessments"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Interviews will be conducted with a subset of participants and may be done up to 6 months after the Week 52/EOS Visit, but before the EOS is declared.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 21
      },
      {
        "id": "annot_2",
        "text": "ePD training only. ePD devices are given to the patients at the baseline visit",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "In the case of minor dental surgery, blood samples can be drawn within 3 days prior to the day of surgery.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Table 4",
        "pageNumber": 3
      },
      {
        "id": "annot_4",
        "text": "Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Cover Page",
        "pageNumber": 1
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1 (electronic 7.0)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-20",
        "description": "Amended Clinical Trial Protocol 05 incorporating statistical testing for secondary endpoints and exit interviews.",
        "amendmentNumber": "5"
      },
      {
        "id": "ver_2",
        "versionNumber": "1 (electronic 5.0)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-13",
        "description": "Amended Clinical Trial Protocol 04",
        "amendmentNumber": "4"
      },
      {
        "id": "ver_3",
        "versionNumber": "1 (electronic 1.0)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-06-17",
        "description": "Original Protocol",
        "amendmentNumber": "Original"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}